Table 2.
Patient and transplant characteristics of the genotyped cohort (N = 48)
| N (% or IQR) | ||
|---|---|---|
| Median Age at HCT | 49 (20–73) | |
| Disease | ||
| AML | 35 (73%) | |
| MDS | 13 (27%) | |
| Disease status at transplant | ||
| CR1 | 32 (67%) | |
| CR2 | 16 (33%) | |
| Donor type | ||
| MRD | 20 (42%) | |
| MUD | 20 (42%) | |
| Haplo | 8 (16%) | |
| Graft type | ||
| BM | 26 (54%) | |
| PBSC | 22 (46%) | |
| Conditioning regimen | ||
| RIC | 25 (52%) | |
| MAC | 23 (48%) | |
| Median FUP (months) | 12.33 (2.4–109.5) | |
| Acute GvHD (II-IV) | 16 (33%) | |
| Chronic GvHD (moderate-severe) | 10 (20%) | |
| Median time of relapse after HCT (months) | 5.8 (1.67–56.3) | |
| DLI recipients | 25 (52%) | |
| Time to DLI (months) | 7.8 (2.9–61.08) | |
| Extramedullary disease at relapse | 4 (8%) | |
IQR interquartile range, HCT hematopoietic cell transplantation, AML acute myeloid leukemia, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasms, MRD matched related donor, MUD matched unrelated donor, MMUD mismatched unrelated donor, Haplo haploidentical donor, BM bone marrow, PBSC peripheral blood stem cells, MAC myeloablative, RIC reduced intensity, GvHD graft versus host disease, DLI donor lymphocyte infusion.